Effect of Rosuvastatin on Cytokines After Traumatic Brain Injury
关键词
抽象
描述
The head injury is a frequent problem of health, which produces high morbid-mortality. Today is the main cause of death and disability between 18 and 40 years. In addition it originates expensive expenses in health care systems.
Head injury produces damage by primary mechanisms related to impact, then by biochemical ways which are activated and they carry to secondary damage. Many studies have been conducted for explaining secondary injury, the majority conclude there is a kind of ischemic lesion related maybe with changes in cerebral flow and metabolism. All these changes are associated to a immunological response. Up to now some drugs are directed to modulate the immunological system, although many of them have been ineffective.
Statins o inhibitors of HMG CoA reductase are drugs used in dyslipidemia, frequently for reduction in LDL. Experimental and clinical studies in stroke have shown improvement in outcome. The toxicity related to statin is myopathy and hepatopathy, both with low incidence without fatal cases. Rosuvastatin has been postulated be the most powerful with longest life and toxicity similar to another statins. Many studies have suggested an important immunomodulator effect after statins administration, The investigators have previously demonstrated the possible effect of statin on amnesia and disorientation improvement with patients who suffered a moderated head injury (Glasgow 9-13). The aim of this new study is to analyze the possible immunomodulator role of statins on head injury.
日期
| 最后验证: | 09/30/2009 |
| 首次提交: | 10/04/2009 |
| 提交的预估入学人数: | 10/04/2009 |
| 首次发布: | 10/05/2009 |
| 上次提交的更新: | 10/04/2011 |
| 最近更新发布: | 10/05/2011 |
| 实际学习开始日期: | 07/31/2009 |
| 预计主要完成日期: | 06/30/2011 |
| 预计完成日期: | 07/31/2011 |
状况或疾病
干预/治疗
Drug: Rosuvastatin
Drug: Placebo
相
手臂组
| 臂 | 干预/治疗 |
|---|---|
| Experimental: Rosuvastatin 20 mg oral during 10 days | Drug: Rosuvastatin 20 mg oral, for 10 days |
| Placebo Comparator: Placebo | Drug: Placebo 20 mg vehicle |
资格标准
| 有资格学习的年龄 | 16 Years 至 16 Years |
| 有资格学习的性别 | All |
| 接受健康志愿者 | 是 |
| 标准 | Inclusion Criteria: - Man or woman > 16 and < 60 years old with HI less 24 hours in progression and Glasgow between < 13 - Acceptance of family to participate (first grade) Exclusion Criteria: - Previous head injury with severe disability - History of neurological or psychiatric disease with severe disability - Administration 24 hrs previous of: fibrates, niacin, ciclosporin, azoles, macrolides, inhibitors of protease, nefazodone, verapamil, diltiazem,amiodarone - Very poor possibilities for survival - Use of Administration of THAM, mannitol, barbiturates, corticosteroids, scavengers of free radicals, inhibitors of lipidic peroxidation, indometacin, calcium antagonist, antagonists of neurotransmitters before randomization - isolated lesions in brain stem - Allergy to the drug - Hepatopathy or myopathy (or) history of this, or clinical data of hepatic disease - Management previous in other Hospital - Pregnancy |
结果
主要结果指标
1. Plasmatic levels of cytokines (IL-1B, IL-6, TNF-alfa) (pg/dL) [Day 3]
次要成果指标
1. Functional outcome by Disability Rating Scale [after 3 months]
2. change of lesions on CT scan [72 hours]
3. Determination of CK, AST, ALT [3rd and 7th day]
4. Amnesia time using GOAT Score [in-patient follow-up, after 3 months]
